FCR001

BIOLOGICAL3 trials

Sponsors

Talaris Therapeutics Inc.

Conditions

Diffuse Cutaneous Systemic SclerosisKidney TransplantationTransplanted Organ Rejection

Phase 1

A Safety and Efficacy Study of FCR001 in Adults With Rapidly Progressive Diffuse Cutaneous Systemic Sclerosis

WithdrawnNCT05098145

Talaris Therapeutics Inc.Diffuse Cutaneous Systemic Sclerosis

Start: 2021-11-24End: 2027-02-28Updated: 2023-10-12

Phase 2

A Safety and Efficacy Study of FCR001 Cell Therapy in Previously Transplanted Living Donor Kidney Recipients

WithdrawnNCT01649388

Talaris Therapeutics Inc.Kidney Transplantation

Start: 2012-10-15End: 2023-02-28Updated: 2023-03-02

Phase 3

A Safety and Efficacy Study of FCR001 vs Standard of Care in de Novo Living Donor Kidney Transplantation

TerminatedNCT03995901

Talaris Therapeutics Inc.Transplanted Organ Rejection

Start: 2019-10-25End: 2023-02-16Updated: 2023-03-03